Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Schrage YM et al. – Using kinome profiling, the authors found the Src pathway to be active in chondrosarcoma. Moreover, the authors showed in vitro that the inhibitor of the Src pathway, dasatinib, may provide a potential therapeutic benefit for chondrosarcoma patients who are not eligible for surgery.

Related Articles

Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/09    Relevance Score: 69%

Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors, Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after Viral Hepatitis
Journal of Clinical Endocrinology and Metabolism, 11/18/09    Relevance Score: 67%

Metastatic potential of an aneurysmal bone cyst
Virchows Archiv, 10/27/09    Relevance Score: 67%

Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases
Seminars in Nuclear Medicine, 10/14/09    Relevance Score: 67%

Benign jaw tumors
Indian Journal of Otolaryngology and Head & Neck Surgery, 10/07/09    Relevance Score: 67%

Today in Bone/Cartilage...keeping you current

Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis
Oncogene, 12/16/09

Mechanisms of breast cancer bone metastasis
Cancer Letters, 12/16/09

Noninvasive Prediction of Fracture Risk in Patients with Metastatic Cancer to the Spine
Clinical Cancer Research, 12/15/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address